title: Vecuronium dose requirement and pupillary response in a patient with olivopontocerebellar atrophy (OPCA).
abstract: OBJECTIVE
  Olivopontocerebellar atrophy (OPCA), a variant of spinocerebellar degeneration (Shy-Drager syndrome), is a systemic degenerative disorder affecting the neurons of multiple nuclei. We investigated the sensitivity to vecuronium and the pupillary responses to various stresses in a patient with OPCA.
  
  
  METHODS
  A 65-yr-old woman with a six-month history of OPCA underwent a left upper lobectomy for lung cancer under propofol-N2O anaesthesia. She had symptoms of dysarthria, bulbar palsy, cerebellar ataxia, Parkinsonism, myosis, pyramidal signs and muscular atrophy of the distal extremities. A cumulative dose-response curve for vecuronium was constructed, and pupillary changes in response to various noxious stimuli were evaluated with concomitant recording of the Spectral-Edge-Frequency 90% (SEF90; the frequency below which 90 percent of the EEG power is located). The dose-response curve for vecuronium and the estimated ED50 value (the 50% blocking dose of vecuronium) in this patient with OPCA were almost identical with those of five ASA I-II patients (27 micrograms.kg-1 vs 31 micrograms.kg-1). The pupil size and the SEF90 did not change after tracheal intubation or surgical stimulation in this patient, while in the control subjects (n = 3), these measures increased in response to both stresses.
  
  
  CONCLUSIONS
  The absence of pupillary and SEF90 responses to noxious stimuli suggests a sensitivity to propofol and/or central autonomic dysfunction in patients with OPCA. Although the dose requirement of vecuronium in this patient was similar to that of the control patients, the effects of neuromuscular blockers may vary depending on the severity of muscle atrophy.
authors.affiliation: Department of Anesthesiology and Reanimatology, Gunma University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kuroda
authors.forename: H
authors.initials: H
authors.lastname: Fukura
authors.forename: N
authors.initials: N
authors.lastname: Saruki
authors.forename: D
authors.initials: D
authors.lastname: Yoshikawa
authors.forename: T
authors.initials: T
authors.lastname: Morita
authors.forename: F
authors.initials: F
authors.lastname: Goto
mesh_terms: D000368:Aged; D018685:Anesthetics, Inhalation / Q000008:administration & dosage; D018686:Anesthetics, Intravenous / Q000008:administration & dosage; D001341:Autonomic Nervous System / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007442:Intubation, Intratracheal; D008175:Lung Neoplasms / Q000601:surgery; D009133:Muscular Atrophy / Q000503:physiopathology; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage*; D009609:Nitrous Oxide / Q000008:administration & dosage; D009849:Olivopontocerebellar Atrophies / Q000503:physiopathology*; D010100:Oxygen / Q000008:administration & dosage; D011013:Pneumonectomy; D015742:Propofol / Q000008:administration & dosage; D011680:Pupil / Q000187:drug effects*; D012815:Signal Processing, Computer-Assisted; D013312:Stress, Physiological / Q000503:physiopathology; D014673:Vecuronium Bromide / Q000008:administration & dosage*
chemical_list: D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous; D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide; D009609:Nitrous Oxide; D010100:Oxygen; D015742:Propofol